PD-1 and CTLA-4 antagonists have revolutionized the treatment of multiple tumor types by increasing the quality of T cell priming by DCs, improving expansion of stem-like T cells, and ‘reviving’ exhausted tumor antigen-specific T cell responses39–41. The gene discussed is CTLA4; the disease is neoplasm.